ArticleCancer letters2003
Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity.
Article in Cancer letters, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Wnt signaling in ovarian tumorigenesis.International journal of gynecological cancer : official journal of the International Gynecological Cancer SocietyPooled it
- Review
- Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer.Genes & diseases · 2023Article
- Autism Spectrum Disorder: Signaling Pathways and Prospective Therapeutic Targets.Cellular and molecular neurobiology · 2021Review
- Review
- MASTL: A novel therapeutic target for Cancer Malignancy.Cancer medicine · 2020Review
- A simplified system for the effective expression and delivery of functional mature microRNAs in mammalian cells.Cancer gene therapy · 2020Article
- The inhibition of BRAF activity sensitizes chemoresistant human ovarian cancer cells to paclitaxel-induced cytotoxicity and tumor growth inhibition.American journal of translational research · 2020Article
- Imatinib mesylate and nilotinib decrease synthesis of bone matrixOncology letters · 2019Article
- Review
- The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: implications in targeted cancer therapies.Laboratory investigation; a journal of technical methods and pathology · 2016Article
- PDGFRα in liver pathophysiology: emerging roles in development, regeneration, fibrosis, and cancer.Gene expression · 2015Review
- Can we safely target the WNT pathway?Nature reviews. Drug discovery · 2014Review
- Characterization of chondrocyte scaffold carriers for cell-based gene therapy in articular cartilage repair.Journal of biomedical materials research. Part A · 2013Article
- Lung cancer-initiating cells: a novel target for cancer therapy.Targeted oncology · 2013Review
- Breast cancer stem cells, pathways and therapeutic perspectives 2011.The Indian journal of surgery · 2013Review
- Article
- Wnt/beta-catenin signaling and small molecule inhibitors.Current pharmaceutical design · 2013Review
- Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases.Human pathology · 2012Article
- Role of Wnt/β-catenin signaling in liver metabolism and cancer.The international journal of biochemistry & cell biology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
Beta-Catenin is a critical transducer of the Wnt signal pathway and plays an important role in many developmental and cellular processes. Deregulation of beta-catenin signaling has been observed in a broad range of human tumors. In this report, we investigated whether tyrosine kinase inhibitor STI-571 could inhibit the beta-catenin signaling activity and hence suppress cell proliferation. Our results demonstrated that STI-571 effectively inhibited the constitutive activity of beta-catenin signaling in human colon cancer cells as well as the Wnt1-induced activation of beta-catenin signaling in HOS, HTB-94, and HEK 293 cells. Furthermore, STI-571 was shown to effectively suppress the proliferation of human colon cancer cells. Finally, we demonstrated that the Wnt1-mediated activation of a GAL4-beta-catenin heterologous transcription system was effectively inhibited by STI-571. Thus, our findings suggest that tyrosine phosphorylation may play an important role in regulating beta-catenin signaling activity, and inhibition of this signaling pathway by STI-571 may be further explored as an important target for alternative/adjuvant treatments for a broader range of human cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.